Top

12-05-2015 | Gout | Article

Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort

Journal: Arthritis Research & Therapy

Authors: Jasvinder A Singh, Kasem S Akhras, Aki Shiozawa

Publisher: BioMed Central

Abstract

Introduction

To assess the comparative effectiveness of febuxostat and allopurinol in reducing serum urate (sUA) levels in a real-world U.S. managed care setting.

Methods

This retrospective study utilized 2009 to 2012 medical and pharmacy claims and laboratory data from a large U.S. commercial and Medicare Advantage health plan. Study patients had at least one medical claim with a diagnosis of gout, at least one filled prescription for febuxostat or allopurinol and at least one sUA measurement post-index prescription. Reduction in sUA was examined using propensity score-matched cohorts, matched on patient demographics (gender, age), baseline sUA, comorbidities, geographic region and insurance type.

Results

The study sample included 2,015 patients taking febuxostat and 14,025 taking allopurinol. At baseline, febuxostat users had a higher Quan-Charlson comorbidity score (0.78 vs. 0.53; P <0.001), but similar age and gender distribution. Mean (standard deviation (SD)) sUA level following propensity score matching among treatment-naïve febuxostat vs. allopurinol users (n = 873 each) were: pre-index sUA, 8.86 (SD, 1.79) vs. 8.72 (SD, 1.63; P = 0.20); and post-index sUA, 6.53 (SD, 2.01) vs. 6.71 (SD, 1.70; P = 0.04), respectively. A higher proportion of febuxostat users attained sUA goals of <6.0 mg/dl (56.9% vs. 44.8%; P <0.001) and <5.0 mg/dl (35.5% vs. 19.2%; P <0.001), respectively. Time to achieve sUA goals of <6.0 mg/dl (346 vs. 397 days; P <0.001) and <5.0 mg/dl was shorter in febuxostat vs. allopurinol users (431 vs. 478 days; P <0.001), respectively. Similar observations were made for overall propensity score-matched cohorts that included both treatment-naïve and current users (n = 1,932 each).

Conclusions

Febuxostat was more effective than allopurinol at the currently used doses (40 mg/day for febuxostat in 83% users and 300 mg/day or lower for allopurinol in 97% users) in lowering sUA in gout patients as demonstrated by post-index mean sUA level, the likelihood of and the time to achieving sUA goals.

Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007–2008. Arthritis Rheum. 2011;63:3136–41.CrossRefPubMed

Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh CK, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum Jan. 2008;58:15–25.CrossRef

Roddy E, Zhang W, Doherty M. Is gout associated with reduced quality of life? A case–control study. Rheumatology (Oxford). 2007;46:1441–4.CrossRef

Singh JA, Strand V. Gout is associated with more comorbidities, poorer health-related quality of life and higher health care utilization in US veterans. Ann Rheum Dis. 2008;67:1310–6.CrossRefPubMed

Lee SJ, Hirsch JD, Terkeltaub R, Khanna D, Singh JA, Sarkin A, et al. Perceptions of disease and health-related quality of life among patients with gout. Rheumatology (Oxford). 2009;48:582–6.CrossRef

Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation. 2007;116:894–900.CrossRefPubMed

Krishnan E. Gout and the risk for incident heart failure and systolic dysfunction. BMJ Open. 2012;2:e000282.PubMedCentralCrossRefPubMed

Krishnan E, Baker JF, Furst DE, Schumacher HR. Gout and the risk of acute myocardial infarction. Arthritis Rheum. 2006;54:2688–96.CrossRefPubMed

Krishnan E, Svendsen K, Neaton JD, Grandits G, Kuller LH. Long-term cardiovascular mortality among middle-aged men with gout. Arch Intern Med. 2008;168:1104–10.CrossRefPubMed

10.

Neogi T. Clinical practice. Gout N Engl J Med. 2011;364:443–52.CrossRefPubMed

11.

Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum. 2004;51:321–5.CrossRefPubMed

12.

Sundy JS, Baraf HS, Yood RA, Edwards NL, Gutierrez-Urena SR, Treadwell EL, et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA. 2011;306:711–20.CrossRefPubMed

13.

Halpern R, Fuldeore MJ, Mody RR, Patel PA, Mikuls TR. The effect of serum urate on gout flares and their associated costs: an administrative claims analysis. J Clin Rheumatol. 2009;15:3–7.CrossRefPubMed

14.

Wu EQ, Patel PA, Mody RR, Yu AP, Cahill KE, Tang J, et al. Frequency, risk, and cost of gout-related episodes among the elderly: does serum uric acid level matter? J Rheumatol May. 2009;36:1032–40.CrossRef

15.

Wu EQ, Patel PA, Yu AP, Mody RR, Cahill KE, Tang J, et al. Disease-related and all-cause health care costs of elderly patients with gout. J Manag Care Pharm. 2008;14:164–75.PubMed

16.

Singh JA, Sarkin A, Shieh M, Khanna D, Terkeltaub R, Lee SJ, et al. Health care utilization in patients with gout. Semin Arthritis Rheum. 2011;40:501–11.PubMedCentralCrossRefPubMed

17.

Ferraz MB, O’Brien B. A cost effectiveness analysis of urate lowering drugs in nontophaceous recurrent gouty arthritis. J Rheumatol May. 1995;22:908–14.

18.

Fels E, Sundy JS. Refractory gout: what is it and what to do about it? Curr Opin Rheumatol. 2008;20:198–202.CrossRefPubMed

19.

Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006;65:1312–24.PubMedCentralCrossRefPubMed

20.

Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, et al. American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken). 2012;64:1431–46.CrossRef

21.

Golub RM, Fontanarosa PB. Comparative effectiveness research: relative successes. JAMA. 2012;307:1643–5.CrossRefPubMed

22.

Rundles RW, Metz EN, Silberman HR. Allopurinol in the treatment of gout. Ann Intern Med. 1966;64:229–58.CrossRefPubMed

23.

Delbarre F, Amor B, Auscher C, de Gery A. Treatment of gout with allopurinol. A study of 106 cases. Ann Rheum Dis. 1966;25:627–33.PubMedCentralPubMed

24.

Sarawate CA, Patel PA, Schumacher HR, Yang W, Brewer KK, Bakst AW. Serum urate levels and gout flares: analysis from managed care data. J Clin Rheumatol. 2006;12:61–5.CrossRefPubMed

25.

Harrold LR, Andrade SE, Briesacher BA, Raebel MA, Fouayzi H, Yood RA, et al. Adherence with urate-lowering therapies for the treatment of gout. Arthritis Res Ther. 2009;11:R46.PubMedCentralCrossRefPubMed

26.

Singh JA, Hodges JS, Asch SM. Opportunities for improving medication use and monitoring in gout. Ann Rheum Dis. 2009;68:1265–70.CrossRefPubMed

27.

Febuxostat 40 mg and 80 mg NDA No. 21–856 Indication: treatment of hyperuricemia in patients with gout. Briefing document for Advisory Committee. Division of Anesthesia, Analgesia, and Rheumatology Products FDA Advisory Committee Meeting, 24 November 2008. http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4387b1-02-Takeda.pdf.

28.

STROBE Statement. Strengthening the reporting of observational studies in epidemiology. Link: http://www.strobe-statement.org/fileadmin/Strobe/uploads/checklists/STROBE_checklist_v4_cohort.pdf. 2007. Accessed 09/06/2012.

29.

Pandya BJ, Riedel AA, Swindle JP, Becker LK, Hariri A, Dabbous O, et al. Relationship between physician specialty and allopurinol prescribing patterns: a study of patients with gout in managed care settings. Curr Med Res Opin. 2011;27:737–44.CrossRefPubMed

30.

Medicare.gov: the official U.S. government site for Medicare. Available at: http://www.medicare.gov/sign-up-change-plans/medicare-health-plans/medicare-advantage-plans/medicare-advantage-plans.html. Accessed 11 August 2012.

31.

Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43:1130–9.CrossRefPubMed

32.

Annemans L, Spaepen E, Gaskin M, Bonnemaire M, Malier V, Gilbert T, et al. Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005. Annals of the Rheumatic Diseases. 2008;67(7):960-966.PubMedCentralCrossRefPubMed

33.

Becker MA, Schumacher Jr HR, Wortmann RL, MacDonald PA, Eustace D, Palo WA, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353:2450–61.CrossRefPubMed

34.

Primatesta P, Plana E, Rothenbacher D. Gout treatment and comorbidities: a retrospective cohort study in a large US managed care population. BMC Musculoskelet Disord. 2011;12:103.PubMedCentralCrossRefPubMed

35.

Rothenbacher D, Primatesta P, Ferreira A, Cea-Soriano L, Rodriguez LA. Frequency and risk factors of gout flares in a large population-based cohort of incident gout. Rheumatology (Oxford). 2011;50:973–81.CrossRef

36.

Sarawate CA, Brewer KK, Yang W, Patel PA, Schumacher HR, Saag KG, et al. Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc. 2006;81:925–34.CrossRefPubMed

37.

Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70:41–55.CrossRef

38.

Schumacher Jr HR, Becker MA, Wortmann RL, Macdonald PA, Hunt B, Streit J, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 2008;59:1540–8.CrossRefPubMed

39.

Kim SC, Schmidt BM, Franklin JM, Liu J, Solomon DH, Schneeweiss S. Clinical and health care use characteristics of patients newly starting allopurinol, febuxostat, and colchicine for the treatment of gout. Arthritis Care Res (Hoboken). 2013;65:2008–14.CrossRef

40.

A multicenter clinical trial of allopurinol to prevent kidney function loss in type 1 diabetes. http://clinicaltrials.gov/show/NCT02017171. 2013. Accessed 07/27/2014.

41.

Singh JA, Hodges JS, Toscano JP, Asch SM. Quality of care for gout in the US needs improvement. Arthritis Rheum. 2007;57:822–9.PubMedCentralCrossRefPubMed